Press Releases Applied Therapeutics, Inc.

Equities

APLT

US03828A1016

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4.28 ^USD	+1.18%		-2.28%	+27.76%

Apr. 15	Applied Therapeutics, Inc. Announces Management Changes	CI
Mar. 28	Applied Therapeutics Shares Slip 13% After FDA Extends Drug Review	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer	Apr. 15	GL
Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024	Apr. 04	GL
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia	Mar. 28	GL
Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results	Mar. 06	GL
Applied Therapeutics Announces $100 Million Private Placement	Feb. 28	GL
Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia	Feb. 28	GL
Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia	Feb. 28	AQ
Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency	Feb. 15	GL
Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency	Feb. 15	AQ
Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy	Jan. 04	GL
Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat for Treatment of Classic Galactosemia	Jan. 04	AQ
Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic Galactosemia	Jan. 03	AQ
Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic Galactosemia	Jan. 03	GL
Applied Therapeutics Reports Third Quarter 2023 Financial Results	Nov. 09	GL
Applied Therapeutics Reports Third Quarter 2023 Financial Results	Nov. 09	AQ
Applied Therapeutics to Present at the UBS Biopharma Conference 2023	Nov. 02	GL
Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday, November 7	Nov. 01	GL
Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday, November 7	Nov. 01	AQ
Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2023 EASD Annual Meeting	23-09-28	GL
Applied Therapeutics Announces Successful Pre-NDA Meeting with the FDA and Confirms Plans to Submit NDA for Govorestat for Treatment of Classic Galactosemia to FDA in Q4 2023	23-09-07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Applied Therapeutics, Inc.

Equities

APLT

US03828A1016

Press Releases

Filters